Filtered By:
Specialty: Drugs & Pharmacology
Condition: Heart Failure
Education: Study

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 249 results found since Jan 2013.

Preservation of left ventricle peak and mean pulse flow blood velocity despite progressive deterioration of cardiac function in a chronic heart failure murine model
J Physiol Pharmacol. 2021 Aug;72(4). doi: 10.26402/jpp.2021.4.11. Epub 2022 Jan 21.ABSTRACTThe goal of this study was to assess the alterations in left ventricle (LV) blood flow velocity patterns in relation to progressive impairment of cardiac function in the course of heart failure (HF) in a unique murine model of chronic HF in Tgαq*44 mice. Doppler- and MRI-based assessments of blood velocity and cardiac performance, respectively, were performed in Tgαq*44 mice at the age of 1, 2, 4, 6, 8 and 12 months as compared with age-matched FVB control mice. One-month-old Tgαq*44 mice displayed elongated early diastolic phase ...
Source: Journal of Physiology and Pharmacology - January 24, 2022 Category: Drugs & Pharmacology Authors: U Tyrankiewicz G Kwiatkowski S Chlopicki Source Type: research

RCTs: Peginesatide in patients with anaemia and chronic kidney disease
Source: N Engl J Med Area: News In the New England Journal of Medicine, researchers report the results of four event-driven, randomised, controlled, open-label trials that compared the efficacy and safety of standard erythropoiesis-stimulating agent (ESA) therapy with peginesatide (Omontys), a peptide based ESA approved in the US in March 2012 for the treatment of anaemia caused by chronic kidney disease in adults who are undergoing dialysis.   The EMERALD 1 and EMERALD 2 studies involved patients undergoing haemodialysis. Cardiovascular safety was evaluated by analysis of an adjudicated composite safety end poin...
Source: NeLM - News - January 24, 2013 Category: Drugs & Pharmacology Source Type: news

Associations of chronic hepatitis C with metabolic and cardiac outcomes
ConclusionsChronic hepatitis C virus infection is independently associated with presence of metabolic conditions (insulin resistance, type 2 diabetes and hypertension) and congestive heart failure.
Source: Alimentary Pharmacology and Therapeutics - February 5, 2013 Category: Drugs & Pharmacology Authors: Z. M. Younossi, M. Stepanova, F. Nader, Z. Younossi, E. Elsheikh Tags: Original Article Source Type: research

Results from A 12 Months, Randomized, Clinical Trial Comparing an Olmesartan/Amlodipine Single Pill Combination to Olmesartan and Amlodipine Monotherapies on Blood Pressure and Inflammation.
CONCLUSION: other than to be more effective in reducing blood pressure, olmesartan/amlodipine single pill combination gave also a major increase of insulin sensitivity and a decrease of inflammatory markers compared to single monotherapies. PMID: 23999037 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutical Sciences - August 30, 2013 Category: Drugs & Pharmacology Authors: Derosa G, Cicero AF, Carbone A, Querci F, Fogari E, D'Angelo A, Maffioli P Tags: Eur J Pharm Sci Source Type: research

Personalizing Anticoagulant and Antiplatelet Therapeutics: A Timely Task
Abstract In spite of new therapeutics and diagnostics, thrombosis‐related diseases including heart failure and stroke remain the leading cause of death globally and a major healthcare burden. Pharmacogenomic studies may reduce the burden of thrombotic diseases by aiding treatment individualization with the most appropriate anti‐coagulant and anti‐platelet therapeutics. Discovering and validating biomarkers for improved personalized treatment of thrombotic diseases will require massive investment. A concerted dedicated effort built upon a public‐private partnership is warranted for addressing this foremost public health concern.
Source: Drug Development Research - October 21, 2013 Category: Drugs & Pharmacology Authors: David Gurwitz Tags: Editorial Source Type: research

Differential Effects of Commercial-Grade and Purified Poloxamer 188 on Renal Function
Abstract Poloxamer 188 (P188) is a non-ionic amphiphilic copolymer with hemorheologic, antithrombotic, anti-inflammatory, and cytoprotective properties. It potentially has clinical utility in diverse diseases, such as acute myocardial infarction, acute limb ischemia, shock, acute stroke, heart failure, and sickle cell crisis. P188 is available as an excipient-grade product, manufactured to National Formulary specifications, which we refer to as P188-NF. During synthesis of P188-NF, polymerization of its polyoxyethylene and polyoxypropylene components generates undesirable low molecular weight (LMW) substances, su...
Source: Drugs in R&D - June 1, 2014 Category: Drugs & Pharmacology Source Type: research